Risk Stratification of Heart Failure in Cardiomyopathies.

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

October 1, 2021

Study Completion Date

November 1, 2022

Conditions
Cardiomyopathy With Unknown Etiology
Interventions
DRUG

etiologic treatment,anti-myocardial remodeling

When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.

DRUG

anti-myocardial remodeling

When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.

DRUG

anti-myocardial remodeling,anti-acute heart failure

When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.

DRUG

Etiological, anti-remodeling and symptom treatment

When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.

Trial Locations (1)

200127

Renji Hospital, Shanghai

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

lead

RenJi Hospital

OTHER

NCT02941315 - Risk Stratification of Heart Failure in Cardiomyopathies. | Biotech Hunter | Biotech Hunter